Results 101 to 110 of about 3,081 (193)

Peripheral neuropathy and BTKis in Waldenström: a response?

Blood Advances
Chiara Briani, Bruno Ferrero, Alessandro Salvalaggio, Simone Ragaini, Enrico Amaducci, Irene Dogliotti, Andrea Visentin, Simone Ferrero   +7 more
openaire   +5 more sources

Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia

Case Reports in Medicine
Waldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo, Corrado Zengarini, Claudio Agostinelli, Elena Sabattini, Michelangelo La Placa, Bianca Maria Piraccini, Alessandro Pileri   +6 more
doaj   +1 more source

Exploring the role of IRF4 in the sensitivity of mantle cell lymphoma cells to Bruton\u27s Tyrosine Kinase inhibitors [PDF]

Introduction and aim: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell lymphoma. Therapy using Bruton’s tyrosine kinase (BTK) inhibitors has improved clinical outcomes but primary and secondary resistance to BTK inhibitor (BTKi) therapy ...
Portnojs, Artjoms
core  

EXPLORING THE SENSITIVITY OF MANTLE CELL LYMPHOMA TO INHIBITORS OF BRUTON’S TYROSINE KINASE [PDF]

, 2019
EXPLORING THE SENSITIVITY OF MANTLE CELL LYMPHOMA TO INHIBITORS OF BRUTON’S TYROSINE KINASE Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma which responds poorly to conventional chemotherapy.
Thompson, Hannah Patricia
core  

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i [PDF]

Blood Advances, 2022
openaire   +2 more sources

P122 | ULTRASOUND ASSESSMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BTK INHIBITORS. CLINICAL AND PHARMACOECONOMIC IMPACT

Haematologica
Background. IWCC and ESMO guidelines (I&EGu) suggest abdominal ultrasound (US) and superficial lymphnodes (SLN) palpation to assess patients with chronic lymphocytic leukemia (CLL) in general practice.
E. Benedetti, M.C. Caparello, B. Bruno, S. Galimberti, E. Bramanti, R. Morganti   +5 more
doaj  

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The Case for BTKi

, 2022
Brem, Elizabeth, O'Brien, Susan M
openaire   +2 more sources

Back from (BTKi) holiday

Blood Advances
Danielle M. Brander, Andrea Sitlinger
openaire   +2 more sources

A Review of Resistance Mechanisms to Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia

Bruton’s Tyrosine Kinase (BTK) inhibitors have become one of the most vital drugs in the therapy of chronic lymphocytic leukemia (CLL). Inactivation of BTK disrupts the B-cell antigen receptor (BCR) signaling pathway, which leads to the inhibition ...
Kamil Wiśniewski, Bartosz Puła
core   +1 more source

The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]

Transl Cancer Res
Szymczyk A, Hus I.
europepmc   +1 more source